18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience

Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls

“…In cases with advanced physiologic imaging, regions of diffusion signal abnormality were hypoperfused in 5 of 6 patients and showed decreased amino acid uptake on 18 F-FDOPA PET scans in 7 of 8 patients (Fig. 4).…”

“…Postprocessing data analysis was performed to determine standardized rCBV by using previously published methods 17 and commercially available software (IB Neuro v2.0; Imaging Biometrics, Elm Grove, Wisconsin). 18 F-FDOPA PET images were obtained for 7 patients as previously described. 18 A high-resolution full-ring ECAT HR or ECAT HRϩ PET scanner (CTI-Siemens, Knoxville, Tennessee) was used to acquire images, which contained either 47 contiguous transaxial sections with a section thickness of 3.…”

“…18 F-FDOPA PET images were obtained for 7 patients as previously described. 18 A high-resolution full-ring ECAT HR or ECAT HRϩ PET scanner (CTI-Siemens, Knoxville, Tennessee) was used to acquire images, which contained either 47 contiguous transaxial sections with a section thickness of 3. …”

Value of 18F-3,4-Dihydroxyphenylalanine PET/MR Image Fusion in Pediatric Supratentorial Infiltrative Astrocytomas: A Prospective Pilot Study

“…A growing body of evidence suggests that PET imaging of brain tumors with amino-acid analogs provides useful insights into tumor metabolism and may play a role in a more precise evaluation of brain tumors (7), especially when correlated with structural MR imaging data (8). When compared with 18 F-FDG, presently the most widely available PET tracer, amino-acid analogs have shown higher sensitivity to gliomas because of the higher tumor-to-normal-tissue background ratios (9).…”

Whole-body PET/MRI in oncology: current status and clinical applications

“…Similar diagnostic image quality on the hybrid PET/MRI and the PET/CT studies was found, with excellent agreement between semiquantitative data (i.e., the tumor-to-reference tissue ratios) of the PET/MRI and PET/CT systems (r = 0.98) [82]. 18 F-FDOPA PET/MRI fusion provides precise anatomical localization of tracer uptake in patients with gliomas, with PET data capable of identifying tumors not visible on MRI [84]. In high-risk differentiated thyroid cancer patients, fused 124-iodine PET/MRI has proven to be superior to 124-iodine PET/CT in detecting lesions, particularly those \10 mm [85].…”